180 related articles for article (PubMed ID: 11255268)
21. Visualization of 5T33 myeloma cells in the C57BL/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma.
Alici E; Konstantinidis KV; Aints A; Dilber MS; Abedi-Valugerdi M
Exp Hematol; 2004 Nov; 32(11):1064-72. PubMed ID: 15539084
[TBL] [Abstract][Full Text] [Related]
22. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens.
Potter M; Wax JS
J Natl Cancer Inst; 1983 Aug; 71(2):391-5. PubMed ID: 6576197
[TBL] [Abstract][Full Text] [Related]
23. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice.
Janz S; Shacter E
Cancer Biochem Biophys; 1995 Jun; 15(1):25-34. PubMed ID: 8536217
[TBL] [Abstract][Full Text] [Related]
24. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice.
Hjorth-Hansen H; Seifert MF; Börset M; Aarset H; Ostlie A; Sundan A; Waage A
J Bone Miner Res; 1999 Feb; 14(2):256-63. PubMed ID: 9933480
[TBL] [Abstract][Full Text] [Related]
25. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
26. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
27. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
28. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Oyajobi BO; Mundy GR
Cancer; 2003 Feb; 97(3 Suppl):813-7. PubMed ID: 12548580
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of a novel IL-10 deficient cell transfer model for colitis.
Ikenoue Y; Tagami T; Murata M
Int Immunopharmacol; 2005 Jun; 5(6):993-1006. PubMed ID: 15829415
[TBL] [Abstract][Full Text] [Related]
31. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
[TBL] [Abstract][Full Text] [Related]
32. [Experimental animal models of multiple myeloma].
Miyakawa Y
Nihon Rinsho; 2007 Dec; 65(12):2211-7. PubMed ID: 18069262
[TBL] [Abstract][Full Text] [Related]
33. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma.
Campbell RA; Manyak SJ; Yang HH; Sjak-Shie NN; Chen H; Gui D; Popoviciu L; Wang C; Gordon M; Pang S; Bonavida B; Said J; Berenson JR
Int J Oncol; 2006 Jun; 28(6):1409-17. PubMed ID: 16685443
[TBL] [Abstract][Full Text] [Related]
34. A murine plasmacytoma model for screening active drugs for human myeloma.
Hiramoto RN; Ghanta VK; Durant JR; Hiramoto NS
Cancer Clin Trials; 1980; 3(4):395-402. PubMed ID: 7428144
[TBL] [Abstract][Full Text] [Related]
35. Plasma cell tumour progression in iMycEmu gene-insertion mice.
Kim JS; Han SS; Park SS; McNeil N; Janz S
J Pathol; 2006 May; 209(1):44-55. PubMed ID: 16482495
[TBL] [Abstract][Full Text] [Related]
36. The SCID mouse model: novel therapeutic targets - lessons from gene transfer.
Pierer M; Müller-Ladner U; Pap T; Neidhart M; Gay RE; Gay S
Springer Semin Immunopathol; 2003 Aug; 25(1):65-78. PubMed ID: 12904892
[TBL] [Abstract][Full Text] [Related]
37. Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma.
Asosingh K
Verh K Acad Geneeskd Belg; 2003; 65(2):127-34. PubMed ID: 12870183
[TBL] [Abstract][Full Text] [Related]
38. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
39. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.
Linden M; Kirchhof N; Kvitrud M; Van Ness B
Leuk Res; 2005 Apr; 29(4):435-44. PubMed ID: 15725478
[TBL] [Abstract][Full Text] [Related]
40. Specific chromosome translocation in pristane-induced plasmacytomas of NZB mice.
Oikawa T; Kuzumaki N; Yamada T
J Natl Cancer Inst; 1984 Feb; 72(2):347-53. PubMed ID: 6582321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]